Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|August 12, 2019

Protein Analyzer Offers Ability to Measure Protein Titer Directly from Bioreactor

The Tridex Protein Analyzer from IDEX offers the ability to directly measure protein titer from a bioreactor in real time.

The Tridex Protein Analyzer from IDEX Health & Science offers the ability to directly measure protein titer from a bioreactor in real time. The analyzer is a compact and an easy-to-use solution for at-line titer monitoring in a bioprocess environment. It is built to ensure that at-line results directly correlate to offline high-performance liquid chromatography methodology.

The biopharma industry has long been seeking an alternative to time-consuming offline methods currently in use, and the measurement of antibody titer is a critical parameter for manufacturing biologics and biosimilars, the company reports. The Tridex Analyzer quickly delivers accurate titer measurements over a dynamic range of 0.1–10 g/L, with minimal sample manipulation for use in R&D and process development.

The Tridex Analyzer is the first protein analyzer on the market built specifically for bioprocess monitoring, according to the company. It uses a unique trap and elute technique to accurately monitor the titer in a bioreactor. It does not require chromatography expertise, specialized training, or extensive method development. The sample flowpath is completely enclosed, lending itself to the requirements of single-use bioprocessing.

The Tridex system also offers the option to connect to an automated sampling system for complete integration into a bioprocessing environment and to deliver actionable results with just a few clicks. IDEX launched the new analyzer in July 2019.

Source: IDEX Health & Science


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.